AU2002305942B2 - Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones - Google Patents

Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones Download PDF

Info

Publication number
AU2002305942B2
AU2002305942B2 AU2002305942A AU2002305942A AU2002305942B2 AU 2002305942 B2 AU2002305942 B2 AU 2002305942B2 AU 2002305942 A AU2002305942 A AU 2002305942A AU 2002305942 A AU2002305942 A AU 2002305942A AU 2002305942 B2 AU2002305942 B2 AU 2002305942B2
Authority
AU
Australia
Prior art keywords
compound
radioprotective
ionizing radiation
exposure
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002305942A
Other languages
English (en)
Other versions
AU2002305942A1 (en
Inventor
Stephen C. Cosenza
Lawrence Helson
Premkumar E. Reddy
Ramana M.V. Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University
Traws Pharma Inc
Original Assignee
Onconova Therapeutics Inc
Temple University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconova Therapeutics Inc, Temple University filed Critical Onconova Therapeutics Inc
Publication of AU2002305942A1 publication Critical patent/AU2002305942A1/en
Application granted granted Critical
Publication of AU2002305942B2 publication Critical patent/AU2002305942B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002305942A 2001-02-28 2002-02-28 Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones Expired AU2002305942B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27199001P 2001-02-28 2001-02-28
US60/271,990 2001-02-28
PCT/US2002/006107 WO2002069892A2 (en) 2001-02-28 2002-02-28 METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES

Publications (2)

Publication Number Publication Date
AU2002305942A1 AU2002305942A1 (en) 2003-03-13
AU2002305942B2 true AU2002305942B2 (en) 2006-10-26

Family

ID=23037934

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002305942A Expired AU2002305942B2 (en) 2001-02-28 2002-02-28 Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones

Country Status (10)

Country Link
US (1) US6667346B2 (enExample)
EP (1) EP1370253B8 (enExample)
JP (1) JP4302986B2 (enExample)
KR (1) KR100850331B1 (enExample)
AT (1) ATE406881T1 (enExample)
AU (1) AU2002305942B2 (enExample)
CA (1) CA2439288C (enExample)
DE (1) DE60228692D1 (enExample)
IL (2) IL157541A0 (enExample)
WO (1) WO2002069892A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2424884C (en) 2000-10-05 2009-12-15 E. Premkumar Reddy Substituted (e)-styryl benzylsulfones for treating proliferative disorders
IL163608A0 (en) * 2002-02-28 2005-12-18 Univ Temple Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
NZ535232A (en) * 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
AU2004289281C1 (en) * 2003-11-14 2011-12-08 Onconova Therapeutics, Inc. Alpha, beta-Unsaturated sulfoxides for treating proliferative disorders
WO2005053682A2 (en) * 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
AU2005222947B2 (en) * 2004-03-16 2010-12-23 Onconova Therapeutics Inc. Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
US8058313B2 (en) 2004-06-24 2011-11-15 Temple University—Of the Commonwealth System of Higher Education Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
AU2005265412B2 (en) * 2004-07-19 2010-09-02 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones
US7537572B2 (en) 2004-10-22 2009-05-26 General Patent, Llc Treatment or pre-treatment for radiation/chemical exposure
US20090306207A1 (en) * 2005-01-05 2009-12-10 Reddy M V Ramana Treatment of Drug-Resistant Proliferative Disorders
US8143453B2 (en) * 2005-02-25 2012-03-27 Temple University—Of the Commonwealth System of Higher Education Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
CA2617147C (en) * 2005-07-29 2014-01-21 Onconova Therapeutics, Inc. Formulation of radioprotective .alpha.,.beta. unsaturated aryl sulfones
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
JP2007302640A (ja) * 2006-05-15 2007-11-22 Natl Inst Of Radiological Sciences 抗放射線被ばく障害剤
JP5275985B2 (ja) * 2006-07-28 2013-08-28 オンコノバ・セラピューティックス・インコーポレーテッド 放射線保護α，β不飽和アリールスルホン類の処方
US8664272B2 (en) 2006-08-30 2014-03-04 Temple University—Of the Commonwealth System of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
CA2663375A1 (en) * 2006-09-15 2008-03-20 Onconova Therapeutics, Inc. Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
EP2091527B1 (en) * 2006-12-13 2016-03-23 Temple University - Of The Commonwealth System of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US20100049284A1 (en) * 2008-05-15 2010-02-25 The Catholic University Of America Use of heat to treat biological systems exposed to damaging radiation
AU2009310352A1 (en) * 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
WO2010039997A2 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
JP5734869B2 (ja) * 2008-12-16 2015-06-17 オンコノバ・セラピューティックス・インコーポレーテッド ヒトにおける細胞毒性物質の有害作用に対する治療レジメンの有効性を決定する方法
EP3025724B1 (en) 2009-05-13 2018-07-11 The University of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
EA022360B1 (ru) * 2010-03-24 2015-12-30 Онконова Терапьютикс, Инк. Композиции и способы для профилактики и лечения ран
CA2792913C (en) * 2010-03-26 2020-01-21 Onconova Therapeutics, Inc. Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone
GB201010359D0 (en) 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
CA2885217C (en) 2012-09-20 2019-10-08 Temple University - Of The Commonwealth System Of Higher Education Substituted alkyl diaryl derivatives, methods of preparation and uses
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
JP6430483B2 (ja) 2013-03-15 2018-11-28 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化学療法の間の正常細胞の一時的な保護
CN104230770B (zh) * 2013-06-17 2017-11-21 华夏生生药业(北京)有限公司 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用
US10195466B2 (en) * 2014-01-06 2019-02-05 Hackensack University Medical Center Method for treating skin cancer using radiation therapy
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US10383831B2 (en) 2015-08-03 2019-08-20 Temple University—Of the Commonwealth System of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
CN106432011B (zh) * 2016-09-18 2018-11-02 中国医学科学院放射医学研究所 一类具有辐射防护作用的新化合物、其制备方法及其药物应用
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
JP7324930B2 (ja) * 2019-07-18 2023-08-10 フアシアシェンシェン ファーマシューティカル ベイジン カンパニー リミテッド カルバメート置換スチリルスルホン類化合物及びその製造方法ならびにその使用
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE284386T1 (de) 1997-10-03 2004-12-15 Univ Temple Styrolsulfone als antikrebsmittel
US6201154B1 (en) * 1999-03-31 2001-03-13 Temple University-Of The Commonwealth Of Higher Education Z-styryl sulfone anticancer agents
WO2000059494A1 (en) * 1999-04-02 2000-10-12 Temple University- Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
WO2000059495A1 (en) * 1999-04-02 2000-10-12 Temple University - Of The Commonwealth System Of Higher Education (e)-styryl sulfone anticancer agents
IL149064A0 (en) * 1999-10-12 2002-11-10 Univ Temple Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
AU2001251391A1 (en) * 2000-04-06 2001-10-23 Acorda Therapeutics, Inc. Compositions and methods for promoting neural regeneration
US6486210B2 (en) 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
DK1379508T3 (da) * 2001-02-28 2011-01-03 Univ Temple N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf

Also Published As

Publication number Publication date
KR100850331B1 (ko) 2008-08-04
CA2439288A1 (en) 2002-09-12
IL157541A0 (en) 2004-03-28
US6667346B2 (en) 2003-12-23
EP1370253B8 (en) 2008-11-26
WO2002069892A2 (en) 2002-09-12
WO2002069892A3 (en) 2002-11-07
US20030060505A1 (en) 2003-03-27
CA2439288C (en) 2011-08-09
KR20030086596A (ko) 2003-11-10
DE60228692D1 (de) 2008-10-16
JP4302986B2 (ja) 2009-07-29
IL157541A (en) 2010-05-31
JP2004525908A (ja) 2004-08-26
EP1370253B1 (en) 2008-09-03
EP1370253A4 (en) 2005-08-17
ATE406881T1 (de) 2008-09-15
EP1370253A2 (en) 2003-12-17

Similar Documents

Publication Publication Date Title
CA2439288C (en) Method for protecting cells and tissues from ionizing radiation toxicity with .alpha.,.beta. unsaturated aryl sulfones
AU2002305942A1 (en) Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones
King et al. Use of amifostine for cytoprotection during radiation therapy: a review
US6646009B2 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
Pilepich et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
BRPI0713660A2 (pt) método de prevenção de danos de tecidos induzidos por radiação nuclear, solar e outras radiações
AU2002306604A1 (en) N-(Aryl)-2-arylethenesulfonamides and therapeutic uses thereof
Shipley et al. Bladder cancer. The selection of patients for treatment by full‐dose irradiation
WO2005065074A2 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
Stewart et al. Radioprotection of two mouse tumors by WR-2721 in single and fractionated treatments
Carnes et al. In vivo protection by the aminothiol WR-2721 against neutron-induced carcinogenesis
Stewart et al. Radioprotection of mouse skin by WR-2721 in single and fractionated treatments
Hazout et al. Historical view of the effects of radiation on cancer cells
JP5196787B2 (ja) 増殖性疾患を治療するためのα，β−不飽和スルホキシド
CN110354133A (zh) 四氢生物蝶呤的应用及药物
Groves et al. Saving normal tissues–a goal for the ages
Rojas et al. Interaction of misonidazole and WR-2721—II. Modification of tumour radiosensitization
JP2007512378A (ja) 放射線障害から保護するためのβ−ラパコンの使用
Chang et al. Advanced head and neck cancer: response to and toxicity of multimodality therapy.
CN110354257B (zh) 鸟苷三磷酸环化水解酶1的应用及药物
Miyatake et al. ACT-02 BORON NEUTRONS CAPTURE THERAPY FOR RECURRENT HIGH-GRADE MENINGIOMAS, FROM REACTOR TO ACCELERATOR
Rich et al. Tumor cell kinetics of human rectal cancer: Relationship between potential doubling time, response to irradiation and chemotherapy, and patterns of failure
CARRANO et al. EJ AINSWORTH, RJM FRY, D. GRAHN
Hogeweg Variations in energy distributions in collimated neutron beams at various energies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
GD Licence registered

Name of requester: ONCONOVA THERAPEUTICS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired